QIAGEN has announced the discontinuation of the NeuMoDx 96 and 288 Molecular Systems in response to changing trends and demand for integrated PCR-based clinical molecular testing systems.
The company intends to focus on the QIAstat-Dx system for syndromic testing, the QIAcuity portfolio of digital PCR systems, and the QIAGEN Digital Insights (QDI) bioinformatics business.
QIAGEN also plans to build its leadership position in Sample technologies and the QuantiFERON-TB franchise. The company claims that it will provide the necessary support for existing NeuMoDx users during the transition, including maintenance, technical support, and the provision of necessary consumables, until 2025.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.